Ieq Capital LLC Has $6.16 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Ieq Capital LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 66,660 shares of the biopharmaceutical company's stock after selling 15,591 shares during the quarter. Ieq Capital LLC's holdings in Gilead Sciences were worth $6,157,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in GILD. HHM Wealth Advisors LLC raised its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 161 shares during the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences in the 4th quarter worth $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the 4th quarter worth $29,000. Finally, Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter valued at about $31,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $0.08 on Friday, reaching $109.95. The stock had a trading volume of 9,729,048 shares, compared to its average volume of 7,379,648. The company has a market capitalization of $137.03 billion, a P/E ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The stock has a fifty day moving average price of $95.41 and a 200-day moving average price of $88.73. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $111.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is 832.43%.

Insiders Place Their Bets

In other news, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 713,000 shares of company stock valued at $67,945,181. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GILD shares. Mizuho lifted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, November 21st. Wolfe Research started coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an "outperform" rating and a $110.00 price target on the stock. Cantor Fitzgerald reissued a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada upped their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.